Narhex Life Sciences (ASX:NLS) acquisition target, ResApp Diagnostics, has enrolled its first patient at Joondalup Health Campus in Western Australia.
The trial will gather data from 150 patients with a variety of respiratory conditions with the aim of further optimising the ResApp algorithms for pneumonia and asthma.
In addition, the trial aims to broaden the validation to other common respiratory conditions such as bronchitis, bronchiolitis and upper respiratory tract conditions.
Preliminary results from this trial are expected within three months.
ResApp is currently finalising ethics approval to commence an additional trial at a second major Australian hospital that will greatly increase the speed in which patient data can be acquired.
The commencement of the trial at Joondalup Health Campus was featured on Channel 7’s Today Tonight on Monday, 23 March 2015.
ResApp, through the exclusive licence it has been granted by the University of Queensland, is developing mobile medical applications for the diagnosis and management of respiratory disease.
Addressable markets for this technology include at-home diagnosis and management of respiratory disease; licensing to large telehealth providers; and working with organisations such as the World Health Organisation to deliver tools for low-cost diagnosis and management of respiratory illness in the developing world.
Cough is the most common single reason for a doctor visit, and in the US, over 100 million primary care physician visits result in diagnosis of a respiratory disease.
According to a recent Rock Health report, US venture capital investment in mHealth for the first half of 2014 represented $2.4 billion, exceeding the total invested in 2013.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.